Last reviewed · How we verify
Td-Impfstoff Merieux
Td-Impfstoff Merieux is a vaccine that stimulates the body's immune response to diphtheria and tetanus.
Td-Impfstoff Merieux is a vaccine that stimulates the body's immune response to diphtheria and tetanus. Used for Prevention of diphtheria and tetanus.
At a glance
| Generic name | Td-Impfstoff Merieux |
|---|---|
| Sponsor | IBSS Biomed S.A. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It works by introducing inactivated diphtheria and tetanus toxins to the body, which triggers an immune response and helps the body develop antibodies to fight these diseases. This immune response can provide long-term protection against diphtheria and tetanus.
Approved indications
- Prevention of diphtheria and tetanus
Common side effects
- Injection site pain
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Td-Impfstoff Merieux CI brief — competitive landscape report
- Td-Impfstoff Merieux updates RSS · CI watch RSS
- IBSS Biomed S.A. portfolio CI